The rise of Sildenafil initially drove a surge for pharma, however recent developments present a uncertain scenario for investors. Off-patent versions are reducing revenue, and ongoing patent challenges add further https://arunlcbd062354.blogpostie.com/62393737/the-blue-pill-and-big-pharma-a-volatile-play